Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis

Cristina Sancricca, Marina Mora, Enzo Ricci, Pietro Attilio Tonali, Renato Mantegazza, Massimiliano Mirabella

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Sporadic inclusion-body myositis (s-IBM) is a chronic progressive inflammatory myopathy leading to severe disability. It has been suggested that statins may benefit s-IBM patients based on their pleiotropic effects on autoimmunity and possible adverse influence of increased cholesterol on muscle pathological changes. We carried out a pilot, open-label trial to evaluate safety and tolerability of oral simvastatin in s-IBM patients. Fourteen patients were treated with 40 mg of simvastatin over 12 months. Primary outcome measures included the assessment tools proposed by International Myositis Outcome Assessment Collaborative Study group and the IBM-Functional Rating Scale. As additional data, we report the results obtained from muscle MRI, biopsy and oropharyngeal scintigraphy. Ten patients completed the trial and the treatment appeared safe and well tolerated. None of the patients showed a significant clinical improvement. Outcome measures used in this study proved to be valuable tools for global assessment of s-IBM patients. At present, we cannot recommend simvastatin as a treatment for s-IBM though our data may warrant a placebo-controlled study.

Original languageEnglish
Pages (from-to)841-847
Number of pages7
JournalNeurological Sciences
Volume32
Issue number5
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Inclusion Body Myositis
Simvastatin
Myositis
Outcome Assessment (Health Care)
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscles
Autoimmunity
Radionuclide Imaging
Cholesterol
Placebos
Biopsy
Safety

Keywords

  • Pilot clinical trial
  • Simvastatin
  • Sporadic inclusion-body myositis

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. / Sancricca, Cristina; Mora, Marina; Ricci, Enzo; Tonali, Pietro Attilio; Mantegazza, Renato; Mirabella, Massimiliano.

In: Neurological Sciences, Vol. 32, No. 5, 10.2011, p. 841-847.

Research output: Contribution to journalArticle

Sancricca, Cristina ; Mora, Marina ; Ricci, Enzo ; Tonali, Pietro Attilio ; Mantegazza, Renato ; Mirabella, Massimiliano. / Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. In: Neurological Sciences. 2011 ; Vol. 32, No. 5. pp. 841-847.
@article{4444bbc65abb41f28e7622f139e01635,
title = "Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis",
abstract = "Sporadic inclusion-body myositis (s-IBM) is a chronic progressive inflammatory myopathy leading to severe disability. It has been suggested that statins may benefit s-IBM patients based on their pleiotropic effects on autoimmunity and possible adverse influence of increased cholesterol on muscle pathological changes. We carried out a pilot, open-label trial to evaluate safety and tolerability of oral simvastatin in s-IBM patients. Fourteen patients were treated with 40 mg of simvastatin over 12 months. Primary outcome measures included the assessment tools proposed by International Myositis Outcome Assessment Collaborative Study group and the IBM-Functional Rating Scale. As additional data, we report the results obtained from muscle MRI, biopsy and oropharyngeal scintigraphy. Ten patients completed the trial and the treatment appeared safe and well tolerated. None of the patients showed a significant clinical improvement. Outcome measures used in this study proved to be valuable tools for global assessment of s-IBM patients. At present, we cannot recommend simvastatin as a treatment for s-IBM though our data may warrant a placebo-controlled study.",
keywords = "Pilot clinical trial, Simvastatin, Sporadic inclusion-body myositis",
author = "Cristina Sancricca and Marina Mora and Enzo Ricci and Tonali, {Pietro Attilio} and Renato Mantegazza and Massimiliano Mirabella",
year = "2011",
month = "10",
doi = "10.1007/s10072-011-0657-6",
language = "English",
volume = "32",
pages = "841--847",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "5",

}

TY - JOUR

T1 - Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis

AU - Sancricca, Cristina

AU - Mora, Marina

AU - Ricci, Enzo

AU - Tonali, Pietro Attilio

AU - Mantegazza, Renato

AU - Mirabella, Massimiliano

PY - 2011/10

Y1 - 2011/10

N2 - Sporadic inclusion-body myositis (s-IBM) is a chronic progressive inflammatory myopathy leading to severe disability. It has been suggested that statins may benefit s-IBM patients based on their pleiotropic effects on autoimmunity and possible adverse influence of increased cholesterol on muscle pathological changes. We carried out a pilot, open-label trial to evaluate safety and tolerability of oral simvastatin in s-IBM patients. Fourteen patients were treated with 40 mg of simvastatin over 12 months. Primary outcome measures included the assessment tools proposed by International Myositis Outcome Assessment Collaborative Study group and the IBM-Functional Rating Scale. As additional data, we report the results obtained from muscle MRI, biopsy and oropharyngeal scintigraphy. Ten patients completed the trial and the treatment appeared safe and well tolerated. None of the patients showed a significant clinical improvement. Outcome measures used in this study proved to be valuable tools for global assessment of s-IBM patients. At present, we cannot recommend simvastatin as a treatment for s-IBM though our data may warrant a placebo-controlled study.

AB - Sporadic inclusion-body myositis (s-IBM) is a chronic progressive inflammatory myopathy leading to severe disability. It has been suggested that statins may benefit s-IBM patients based on their pleiotropic effects on autoimmunity and possible adverse influence of increased cholesterol on muscle pathological changes. We carried out a pilot, open-label trial to evaluate safety and tolerability of oral simvastatin in s-IBM patients. Fourteen patients were treated with 40 mg of simvastatin over 12 months. Primary outcome measures included the assessment tools proposed by International Myositis Outcome Assessment Collaborative Study group and the IBM-Functional Rating Scale. As additional data, we report the results obtained from muscle MRI, biopsy and oropharyngeal scintigraphy. Ten patients completed the trial and the treatment appeared safe and well tolerated. None of the patients showed a significant clinical improvement. Outcome measures used in this study proved to be valuable tools for global assessment of s-IBM patients. At present, we cannot recommend simvastatin as a treatment for s-IBM though our data may warrant a placebo-controlled study.

KW - Pilot clinical trial

KW - Simvastatin

KW - Sporadic inclusion-body myositis

UR - http://www.scopus.com/inward/record.url?scp=80054715362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054715362&partnerID=8YFLogxK

U2 - 10.1007/s10072-011-0657-6

DO - 10.1007/s10072-011-0657-6

M3 - Article

VL - 32

SP - 841

EP - 847

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 5

ER -